No Data
No Data
Aligos Therapeutics Advances Pipeline Amid Financial Challenges
Aligos Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results and Missed Its EPS Estimate.
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Aligos Therapeutics | 10-K: Annual report
Aligos Therapeutics | 8-K: Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
Aligos Therapeutics 4Q Loss/Shr $13.08 >ALGS